Novel cancer vaccines

Bibliography

• PARDOLL DM: Cancer vaccines. Nat. Med.(1998) 4(5):525–531.
   PubMedGoogle Scholar
• ••An in-depth review of the contemporarycancer vaccine approaches aimed at exposing cancer antigens to the cellular arm of the immune system and the prospects for therapeutic cancer vaccines.
   Google Scholar
• OVERWIJK W, RESTIFO N: Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol.(2001) 22(1):5. A concise review of the new challenge the field of tumour immunology faces and the future direct of cancer vaccine research.
   Google Scholar
• MONZAVI-KARBASSI B, KIEBER-EMMONS T: Current concepts in cancer vaccine strategies. Biotechniques(2001) 30(1):170–189.
   PubMedGoogle Scholar
• ••A critical review of current perspectives andfuture strategies for active specific immunotherapy of cancers, particularly the use of tumour-derived Hsps and carbohydrate antigens in tumour vaccines.
   Google Scholar
• DE GRUIJL T D, CURIEL D T: Cancer vaccine strategies get bigger and better. Nat. Med.(1999) 5(10):1124–1125.
   PubMedGoogle Scholar
• OFFRINGA R, VAN DER BURG SH, OSSENDORP F et al.:Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. brununol.(2000) 12(5):576–582.
   Google Scholar
• ••A comprehensive review on the need forvaccine formulations comprising defined antigens and on the antigenic composition of such vaccines, as well as on the importance of accurate methodologies for the evaluation of vaccine-induced T-cell responses.
   Google Scholar
• KIESSLING R, PAWELEC G, WELSH R M etal.:Have tumor cells learnt from microorganisms how to fool the immune system? Ma Med. Today(2000) 6(9):344–346.
   Google Scholar
• CHOUAIB S, ASSELIN-PATUREL C, MAMI-CHOUAIB F et al:The host-tumor immune conflict: from immunosuppression to resistance and destruction. bronuriol. Today(1997) 18(10):493–497.
   PubMedGoogle Scholar
• MITCHELL D A, NAIR S K: RNA-transfected dendritic cells in cancer immunotherapy. j Clin. Invest.(2000) 106(9):1065–1069.
   PubMedGoogle Scholar
• ••Provides an in-depth review of theadvantages and disadvantages of employing RNA transfection in loading dendritic cells with tumour antigens.
   Google Scholar
• BELLONE M, IEZZI G, IMRO MA et al:Cancer immunotherapy: synthetic and natural peptides in the balance. bronuriol Today(1999) 20(10):457–462.
   PubMedGoogle Scholar
• BIRAGYN A, KWAK LW: Designer cancer vaccines are still in fashion. Nat. Med.(2000) 6(9):966–968.
   PubMedGoogle Scholar
• DALLAL R M, LOTZE M T: The dendritic cell and human cancer vaccines. Corr. Opiri. Immortal.(2000) 12(5):583–588.
   PubMedGoogle Scholar
• •Provides a basic scientific overview of dendritic cell biology and an update on clinical trials of dendritic cell-based vaccine strategies for the treatment of cancer.
   Google Scholar
• MOINGEON P: Cancer vaccines. Vaccine(2001) 19(11-12):1305–1326.
   PubMedGoogle Scholar
• COLACO CA: Why are dendritic cells central to cancer immunotherapy? Med. Today (1999)5(1):14–17.
   Google Scholar
• VAN DEN EYNDE BJ, VAN DER BRUGGEN P: T cell defined tumor antigens. Curl: Opiri. bronuriol.(1997) 9(5):684–693.
   Google Scholar
• ••A comprehensive review of currentmethods used for identification of tumour associated antigens, the tumour antigens identified to date and the implications of those antigens for antitumour therapy.
   Google Scholar
• YEE C, RIDDELL SR, GREENBERG PD: Prospects for adoptive T cell therapy. Curl: Opiri. bronuriol.(1997) 9(5):702–708.
   Google Scholar
• SALGALLER ML, THURNHER M, BARTSCH G et al.:Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Cancer(1999) 86(12):2674–2683.
   PubMedGoogle Scholar
• ••A detailed report of the InternationalUnion Against Cancer Tumour Biology Committee Workshop on the use of dendritic cells in cancer clinical trials.
   Google Scholar
• MACH N, DRANOFF G: Cytokine-secreting tumor cell vaccines. Corr. Opiri. bronuriol(2000) 12(5):571–575.
   Google Scholar
• •A critical review of recent studies using genetically modified tumour cells to augment the host antitumour response with particular references to experiments involving IL-12 and GM-CSE
   Google Scholar
• CHEN W RAINS N, YOUNG D et al:Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer? J. Gastroenterol Hepatol(2000) 15(7):698–705.
   Google Scholar
• OCKERT D, SCHMITZ M, HAMPL M et al.:Advances in cancer immunotherapy. bronuriol Today(1999) 20(2):63–65.
   PubMedGoogle Scholar
• CHUNG-FAYE GA, KERR DJ: Innovative treatment for colon cancer. Br. Med.(2000) 321(7273):1397–1399.
   PubMedGoogle Scholar
• HARTGERS FC, FIGDOR CG, ADEMA GJ: Towards a molecular understanding of dendritic cell immunobiology. bronuriol. Today(2000) 21(11):542–545.
   PubMedGoogle Scholar
• SOKOLOFF M H, VOGELZANG N: The ongoing evolution of dendritic cell therapy. Cancer(1999) 86(12):2593–2596.
   PubMedGoogle Scholar
• STEINMAN R M: Dendritic cells and immune-based therapies. Exp. Hematol.(1996) 24(8):859–862.
   PubMedGoogle Scholar
• NESTLE F 0, ALIJAGIC S, GILLIET M et al:Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med.(1998) 4(3):328–332.
   PubMed Web of Science ®Google Scholar
• •One of the pioneering clinical studies on dendritic cell-based immunotherapy for human cancers.
   Google Scholar
• GONG J, CHEN D, KASHIWABA M et al.:Induction of antitumor activity by immunisation with fusions of dendritic and carcinoma cells. Nat. Med.(1997) 3(5):558–61.
   PubMed Web of Science ®Google Scholar
• JENNE L, SCHULER G, STEINKASSERER A: Viral vectors for dendritic cell-based immunotherapy. Trends Immortal.(2001) 22(2):102–107.
   PubMed Web of Science ®Google Scholar
• ••An excellent review that evaluates the viralvectors currently being developed for use in dendritic cell-based immunotherapy.
   Google Scholar
• JONES TR, OBALDIA N, III, GRAMZINSKI RA et al.:Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine(1999) 17(23-203065–3071.
   Google Scholar
• •The first study showing that oligodeoxynudeotides containing CpG motifs enhance immunogenicity of peptide immunogens in non-human primates and may have the potential use as adjuvants for humans
   Google Scholar